India’s quest to lead in innovative medicines is hindered by regulatory bottlenecks and manpower shortages, risking its global competitiveness against China’s rising pharmaceutical dominance.
India’s pharmaceutical industry has spent years building scale, but the country’s regulators have not kept pace, creating a bottleneck that now threatens its push into innovative medicines. Business Standard argues that the Central Drugs Standard Control Organisation needs far deeper scientific and administrative capacity if India wants to compete in biologics, cell therapies and other frontier areas where approval quality is as important as manufacturing strength.
That gap matters because the value of a new drug is realised only after a regulator can judge its safety, efficacy and quality with speed and credibility. According to the article, India still relies heavily on external expert panels for complex first-in-human applications, rather than on a permanent in-house cadre of specialists. The result, it says, is visible in early-stage research: between 2008 and 2022, India registered and conducted only 220 Phase-I trials, far below China’s 2,842 during 2011-20. Business Standard also notes that China’s share of the global innovative-drug pipeline has risen sharply over the past decade.
The reform case has already gained policy traction. In February, Business Standard reported that CDSCO was moving towards risk-based audits and a dedicated scientific cadre of 1,500 experts to close capacity gaps and bring Indian regulation closer to global standards. Economic Times later reported that around 40% of those posts could be filled by contract specialists in fields including microbiology, biotechnology and biostatistics, while Moneycontrol said the government had agreed in principle to the creation of the cadre. Taken together, those reports suggest New Delhi sees regulatory science as part of industrial strategy, not just an administrative chore.
Yet manpower is only one problem. India has more than 10,500 drug manufacturing units, but as of December 2023 only 201 drug inspectors were in post against a sanctioned strength of 504, the Business Standard article says. It also points to a structural weakness in the split between central and state regulators, which can leave inspection findings, licence data and enforcement action trapped in separate systems. Without a common national database, a serious breach flagged in one state may not be reflected quickly enough elsewhere.
The broader stakes are strategic. China’s rise in drug innovation, backed by regulatory capacity, state support and faster review systems, has altered the global balance in pharmaceutical development, while India still remains best known for generics. Business Standard says India’s innovative pipeline has grown, but not fast enough to match rivals, even as the domestic pharmaceutical market and the wider bioeconomy are expected to expand strongly by 2030. The article’s central warning is clear: if India wants to become a major destination for early-stage drug development, it must stop treating regulation as a constraint and start treating it as core infrastructure.
Disclaimer: This article is intended to inform and educate, not to recommend or endorse any financial product, investment or strategy. Please consider your own financial circumstances and seek professional advice where appropriate before making financial decisions.
